Decreased level of PDCD4 (programmed cell death 4) protein activated cell proliferation in the lung of A/J mouse

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 5, 2010, Pages 285-293

  Hwang, Soon Kyung ^a   Minai Tehrani, Arash ^a   Lim, Hwang Tae ^a   Shin, Ji Young ^a   An, Gil Hwan ^b   Lee, Kee Ho ^c,d   Park, Kee Rang ^e   Kim, Yeon Soo ^f   Beck Jr , George ^g   Yang, Hsin Sheng ^h   Cho, Myung Haing ^a  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Division of Radiation Cancer Research   (South Korea)

^d Korean Institute of Radiological and Medical Sciences   (South Korea)

^e Juseong College   (South Korea)

^f Inje University   (South Korea)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

Author keywords

aerosol gene delivery; lung cell proliferation; shRNA Pdcd4

Indexed keywords

MEMBRANE PROTEIN; PROGRAMMED CELL DEATH 4 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

A J MOUSE; AEROSOL; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; LENTIVIRINAE; LUNG ALVEOLUS CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL PROLIFERATION; DOWN-REGULATION; GENETIC VECTORS; HUMANS; LENTIVIRUS; LUNG; MALE; MICE; MICE, INBRED A; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TOR SERINE-THREONINE KINASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77958149807     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0778     Document Type: Article

References (31)

1. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, and Honjo T: Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene. 1995;166:297-301.
2. Young MR, Yang HS, and Colburn NH: Promising molec¬ular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol. Med. 2003;9:36-41.
3. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S, and Colburn NH: Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 1999;96: 14037-14042.
4. Bjornsti MA, and Houghton P: The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335-348.
5. Thomas G, and Hall MN: TOR signaling and control of cell growth. Curr Opin Cell Biol. 1997;9:782-787.
6. Boyd D, Florent G, Kim P, and Brattain M: Determination of the levels of urokinases and its receptor in human colon carcinoma cell line. Cancer Res. 1988;48:3112-3116.
7. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, and Arens N: The urokinase-system\role of cell prolif¬eration and apoptosis. Histol Histopathol. 2008;23:227-236.
8. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, and Allgayer H: Tumor suppressor Pdcd4 inhibits invasion= intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 2007;26: 4550-4562.
9. Hwang SK, Jin H, Kwon JT, Chang SH, Kim TH, and Cho CS: Aerosol-delivered programmed cell death 4 enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice. Gene Ther. 2007a;14:1353-1361.
10. Hwang SK, Kwon JT, Park SJ, Chang SH, Lee ES, and Chung YS: Lentivirus-mediated carboxyl-terminal modulator pro¬tein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther. 2007b;14:1721-1730.
11. Li Y, and Cozzi PJ: Targeting uPA=uPAR in prostate cancer. Cancer Treat Rev. 2007;33:521-527.
12. Hara K, Yonezawa K, Weng QP, Kozolwski MT, Belham C, and Avruch J: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998;273:14484-14494.
13. Jansen AP, Camalier CE, Stark C, and Colburn NH: Char¬acterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 2004;3:103-110.
14. Göke R, Barth P, Schmidt A, Samans B, and Lankat-Buttgereit B: Programmed cell death protein 4 suppresses CDK1=cdc2 via induction of p21(Waf1=Cip1). Am J Physiol Cell Physiol. 2004;287:C1541-C1546.
15. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, and Weller M: Bcl-2 promotes migration and invasivesness of human glioma cells. FEBS Lett. 1998;440:419-424.
16. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, and Rao JS: Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K=AKT pathway. Int J Oncol. 2007;31:19-27.
17. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, and Goltzman D: Urokinase overproduction results in in¬creased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994;54:2372-2377.
18. Konakova M, Hucho F, and Schleuning WD: Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem. 1998;253:421-429.
19. Lawlor MA, and Alessi DR: PKB=Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001; 114:2903-2910.
20. Navé BT, Ouwens M, Withers DJ, Alessi DR, and Shepherd PR: Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344:427-431.
21. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004;167: 399-403.
22. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, and Pagano M: S6K1-and beta TRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006;314:467-471.
23. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, and Colburn NH: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003;23:26-37.
24. Han S, Khuri FR, and Roman J: Fibronection stimulates non-small cell lung carcinoma cell growth through activation of Akt=mammalian target of rapamycin=S6kinase and inacti-vation of LKB1=AMP-activated protein kinase signal path¬ways. Cancer Res. 2006;66:315-323.
25. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, and Slingerland JM: mTOR-raptor binds and activates SGK 1 to regulate p27 phosphorylation. Mol Cell. 2008;30:701-711.
26. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, and Roussel MF: Identification and properties of an atypical catalytic subunit (p34PSK-J3=cdk4) for mammalian D type G1 cyclins. Cell. 1992;71:323-334.
27. Meyerson M, and Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14:2077-2086.
28. Fukami-Kobayashi J, and Mitsui Y: Cyclin D1 inhibits cell proliferation through binding to PCNA and Cdk2. Exp Cell Res. 1999;246:338-347.
29. Jin H, Kim TH, Hwang SK, Chang SH, Kim HW, and Anderson HK: Aerosol delivery of urocanic acid-modified chitosan=programmed cell death 4 complex regulated apo-ptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther. 2006;5:1041-1049.
30. El-Deiry WS, Tokino T, Velculesco VE, Levy DB, Parsons R, and Trent JM: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
31. Sherr CJ, and Roberts JM: CDK inhibitors: positive and negative regulators of the G1-phase progression. Genes Dev. 1999;13:1501-1512.